The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease
Abstract
Objective: Pulmonary hypertension (PH) is an important cause of mortality in systemic sclerosis (SSc), where it can be isolated (pulmonary arterial hypertension [PAH]) or associated with interstitial lung disease (ILD). This study was undertaken to characterize determinants of survival among SSc patients with either type of PH who received PAH‐specific therapy. Methods: Consecutive SSc patients with PAH or ILD‐associated PH confirmed by right heart catheterization were included in the study. Kaplan‐Meier and Cox proportional hazards models were used to compare survival between SSc patients with PAH and those with ILD‐associated PH and to identify predictors of survival. Results: Fifty‐nine patients (39 with PAH and 20 with ILD‐associated PH) were identified. The majority (15 of 20 with ILD‐associated PH and 27 of 39 with PAH) received an endothelin receptor antagonist as initial therapy. Median followup time was 4.4 years (range 2.7–7.4 years). Survival was significantly worse in SSc patients with ILD‐associated PH than in those with PAH (1‐, 2‐, and 3‐year survival rates 82%, 46%, and 39% versus 87%, 79%, and 64%, respectively; P < 0.01 by log rank test). In a multivariable analysis, ILD‐associated PH was associated with a 5‐fold increase in risk of death compared with PAH. Pulmonary vascular resistance index was also an independent predictor of mortality in the overall cohort (hazard ratio 1.05, P < 0.01) and was a significant univariable risk factor in each group separately. Type of initial PAH therapy and the use of warfarin were not related to survival. Conclusion: Survival in SSc complicated by PH remains poor despite currently available treatment options. While therapy may be associated with improved survival in PAH compared with historical controls, the prognosis for patients with ILD‐associated PH is particularly grim. Early diagnosis and treatment may improve outcomes since worsening hemodynamic factors were associated with reduced survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scleroderma (systemic sclerosis): classification, subsets and pathogenesis
(2001) · Classic Papers in Rheumatology · doi:10.3109/9780203214237-95 · Cited by 3,950
Bosentan Therapy for Pulmonary Arterial Hypertension
Rubin, L. J., Badesch, D. B., Barst, R. J., Galiè, N., Black, C. M., Keogh, A., Pulido, T., Frost, A., Roux, S., Leconte, I., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012212 · Cited by 2,726
Sildenafil Citrate Therapy for Pulmonary Arterial Hypertension
Galiè, N., Ghofrani, H. A., Torbicki, A., Barst, R. J., Rubin, L. J., Badesch, D., Fleming, T., Parpia, T., Burgess, G., Branzi, A., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050010 · Cited by 2,476
Clinical classification of pulmonary hypertension
Simonneau, G., Galiè, N., Rubin, L. J., Langleben, D., Seeger, W., Domenighetti, G., Gibbs, S., Lebrec, D., Speich, R., Beghetti, M., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.02.037 · Cited by 1,897
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationChanges in causes of death in systemic sclerosis, 1972–2002
Steen, V. D., & Medsger, T. A. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.066068 · Cited by 1,528
SIMONNEAU, G., BARST, R. J., GALIE, N., NAEIJE, R., RICH, S., BOURGE, R. C., KEOGH, A., OUDIZ, R., FROST, A., BLACKBURN, S. D., et al. (2002) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.165.6.2106079 · Cited by 1,441
Criteria for the classification of early systemic sclerosis.
LeRoy, E. C., & Medsger, T. A. (2001) · PubMed · Cited by 1,384
Reference spirometric values using techniques and equipment that meet ATS recommendations.
Terrin, M. (1981) · PubMed · doi:10.1164/arrd.1981.124.6.763c · Cited by 1,374
Sample-Size Formula for the Proportional-Hazards Regression Model
Schoenfeld, D. A. (1983) · Biometrics · doi:10.2307/2531021 · Cited by 1,096
Cited by
Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., Coffey, C. S., Frost, A., Barst, R. J., Badesch, D. B., Elliott, C. G., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.898122 · Cited by 1,547
Tyndall, A. J., Bannert, B., Vonk, M., Airò, P., Cozzi, F., Carreira, P. E., Bancel, D. F., Allanore, Y., Müller-Ladner, U., Distler, O., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.114264 · Cited by 1,443
Self-citationKurland, G., Deterding, R. R., Hagood, J. S., Young, L. R., Brody, A. S., Castile, R. G., Dell, S., Fan, L. L., Hamvas, A., Hilman, B. C., et al. (2013) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201305-0923st · Cited by 462
Characterization of Connective Tissue Disease-Associated Pulmonary Arterial Hypertension From REVEAL
Chung, L., Liu, J., Parsons, L., Hassoun, P. M., McGoon, M., Badesch, D. B., Miller, D. P., Nicolls, M. R., & Zamanian, R. T. (2010) · Chest · doi:10.1378/chest.10-0260 · Cited by 431
Self-citationManagement of interstitial lung disease associated with connective tissue disease
Mathai, S. C., & Danoff, S. K. (2016) · BMJ · doi:10.1136/bmj.h6819 · Cited by 328
Self-citation
Metadata
- Authors
- Mathai, S. C., Hummers, L. K., Champion, H. C., Wigley, F. M., Zaiman, A., Hassoun, P. M., & Girgis, R. E.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2009-01-29
- Volume
- 60
- Issue
- 2
- Pages
- 569-577
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2003012980
- Cited by
- 265
- References
- 45
- FWCI
- 18.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease. https://app.cochat.ai/papers/10.1002/art.24267
- The paper
- Mathai, S. C., Hummers, L. K., Champion, H. C., Wigley, F. M., Zaiman, A., Hassoun, P. M., & Girgis, R. E. (2009). Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: Impact of interstitial lung disease. Arthritis & Rheumatism. https://doi.org/10.1002/art.24267
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.